Pfizer Halts Cholsterol-Drug Trial

Bank of New York, Mellon to merge; Justice Dept. wants more info on CBOT/Chicago Merc deal; plus more stocks in the news Monday

Pfizer (PFE) stopped all torcetrapib (cholesterol drug) trials following the Data Safety Monitoring Board's recommendation that Pfizer terminate a study due to the imbalance of mortality and cardiovascular events. Sees 2007 and 2008 revenue similar to 2006.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.